Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Obsidian TherapeuticsOBX 11 EV-to-OCF is -20.73 as of Sep. 22, 2026. GuruFocus rates OBX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,403 Biotechnology companies, Obsidian Therapeutics ranks better than 82.54% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Obsidian Therapeutics's Enterprise Value is $1,028.96 Mil.
Obsidian Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-49.64 Mil. Therefore, Obsidian Therapeutics's EV-to-OCF for today is -20.73.
The historical rank and industry rank for Obsidian Therapeutics's EV-to-OCF or its related term are showing as below:
OBX'
s EV-to-OCF Range Over the Past 10 Years
Min: -21.76 Med: 0 Max: -11.13
Current: -20.73
During the past 9 years, the highest EV-to-OCF of Obsidian Therapeutics was -11.13. The lowest was -21.76. And the median was .
OBX's EV-to-OCF is ranked better than 82.54% of 1403
companies
in the Biotechnology industry
Industry Median: -3.36
vs OBX: -20.73
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Obsidian Therapeutics's PE Ratio (TTM) for today is calculated as:
Obsidian Therapeutics's share price for today is $17.33.
Obsidian Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $161.866.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Obsidian Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Obsidian Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Obsidian Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Obsidian Therapeutics's EV-to-OCF falls into.
Obsidian Therapeutics's current Enterprise Value is $1,028.96 Mil.
Obsidian Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Obsidian Therapeutics (OBX) has a EV-to-OCF of -20.73 as of Sep. 22, 2026. According to the industry distribution chart, Obsidian Therapeutics ranks #245 out of 1403 companies in the Biotechnology industry, placing it in the top 17.5%.
Is Obsidian Therapeutics' EV-to-OCF too high?
Obsidian Therapeutics' current EV-to-OCF is -20.73. Based on the distribution chart, Obsidian Therapeutics ranks #245 out of 1403 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Obsidian Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Obsidian Therapeutics' EV-to-OCF compare to LXRX and SLNCF?
According to the Biotechnology industry distribution chart, Obsidian Therapeutics ranks #245 out of 1403 companies for EV-to-OCF. This places Obsidian Therapeutics in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Obsidian Therapeutics's current EV-to-OCF is -20.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Obsidian Therapeutics stock overvalued right now?
Obsidian Therapeutics (OBX) has a current EV-to-OCF of -20.73. The current EV-to-OCF is -20.73. Obsidian Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Obsidian Therapeutics (OBX), the current EV-to-OCF is -20.73 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
11GF Score
Get the complete analysis for OBX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OBX has been successfully added to your 
